RECIST
Health Care Term
2. Partial Response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions
3. Stable Disease (SD): no significant change in tumor size
4. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions
RECIST has become widely adopted as the standard criteria for tumor response evaluation in clinical trials for a variety of solid tumors. Following the RECIST guidelines in cancer research and treatment allows for consistency in data analysis and interpretation, thus helping healthcare providers make more informed decisions regarding cancer treatment.
More Glossary Terms Beginning with R
-
Radiolabeling
Health Care Term Letter: R
-
Radiopharmaceutical
Health Care Term Letter: R
-
Randomized Clinical Trial
Health Care Term Letter: R
-
Rate of Change ROC
Technical Indicator Letter: R
-
Rating Agency Condition
Financial Term Letter: R
-
Reagent
Health Care Term Letter: R
-
Receivables From Customers
Financial Term Letter: R
-
Receivables Turnover Ratio
Fundamental Analysis Letter: R
-
Receptor
Health Care Term Letter: R
-
Recession
Economy Term Letter: R
-
RECIST
Health Care Term Letter: R
-
Recombinant
Health Care Term Letter: R
